Hans Basun

Nya antikroppsbehandlingar mot alzheimers sjukdom: Behov av nationell förberedelse och samordning

Granberg, Tobias; Börjesson Hanson, Anne; Fällmar, David; Basun, Hans et al.

Part of Läkartidningen, 2024

Nya antikroppsbehandlingar mot Alzheimers sjukdom: [New Alzheimer’s treatments: a need for national preparations and coordination]

Granberg, Tobias; Börjesson Hanson, Anne; Fällmar, David; Basun, Hans et al.

Part of Läkartidningen, 2024

Kognitiva sjukdomar

Basun, Hans; Kilander, Lena

Part of Psykiatri, Studentlitteratur AB, 2024

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

Johannesson, Malin; Sahlin, Charlotte; Söderberg, Linda; Basun, Hans et al.

Part of Molecular and Cellular Neuroscience, 2021

• DOI for Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

Alzheimers sjukdom – diagnostik och behandling i dag och i framtiden

Bogdanovic, Nenad; Hansson, Oskar; Zetterberg, Henrik; Basun, Hans et al.

Part of Läkartidningen, 2020

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

Johannesson, Malin; Sahlin, Charlotte; Söderberg, Linda; Basun, Hans et al.

Part of Molecular and Cellular Neuroscience, 2021

• DOI for Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

Alzheimers sjukdom – diagnostik och behandling i dag och i framtiden

Bogdanovic, Nenad; Hansson, Oskar; Zetterberg, Henrik; Basun, Hans et al.

Part of Läkartidningen, 2020

Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study

Jernerén, Fredrik; Cederholm, Tommy; Refsum, Helga; Smith, A. David et al.

Part of Journal of Alzheimer's Disease, p. 189-197, 2019

• DOI for Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study

Rapid amyloid-β oligomer and protofibril accumulation in traumatic brain injury

Abu Hamdeh, Sami; Rollman Waara, Erik; Möller, Christer; Söderberg, Linda et al.

Part of Brain Pathology, p. 451-462, 2018

• DOI for Rapid amyloid-β oligomer and protofibril accumulation in traumatic brain injury

Does Fatty Acid Composition in Subcutaneous Adipose Tissue Differ between Patients with Alzheimer's Disease and Cohabiting Proxies?

Faxen-Irving, Gerd; Falahati, Farshad; Basun, Hans; Eriksdotter, Maria et al.

Part of Journal of Alzheimer's Disease, p. 515-519, 2018

• DOI for Does Fatty Acid Composition in Subcutaneous Adipose Tissue Differ between Patients with Alzheimer's Disease and Cohabiting Proxies?

DHA-rich n-3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study

Karimi, Mohsen; Vedin, Inger; Levi, Yvonne Freund; Basun, Hans et al.

Part of American Journal of Clinical Nutrition, p. 1157-1165, 2017

• DOI for DHA-rich n-3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study

Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimer's Disease

Almkvist, Ove; Rodriguez-Vieitez, Elena; Thordardottir, Steinunn; Amberla, Kaarina et al.

Part of Journal of the International Neuropsychological Society, p. 195-203, 2017

• DOI for Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimer's Disease

High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease

Gunnarsson, Malin Degerman; Ingelsson, Martin; Blennow, Kaj; Basun, Hans et al.

Part of Alzheimer's Research & Therapy, 2016

• DOI for High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease
• Download full text (pdf) of High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease

Safety and tolerability of BAN2401 - a clinical study in Alzheimer's disease with a protofibril selective A beta antibody

Logovinsky, Veronika; Satlin, Andrew; Lai, Robert; Swanson, Chad et al.

Part of Alzheimer's Research & Therapy, 2016

• DOI for Safety and tolerability of BAN2401 - a clinical study in Alzheimer's disease with a protofibril selective A beta antibody
• Download full text (pdf) of Safety and tolerability of BAN2401 - a clinical study in Alzheimer's disease with a protofibril selective A beta antibody

Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study

Eriksdotter, Maria; Vedin, Inger; Falahati, Farshad; Freund-Levi, Yvonne et al.

Part of Journal of Alzheimer's Disease, p. 805-812, 2015

• DOI for Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study

Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study

Freund Levi, Y; Vedin, I; Cederholm, Tommy; Basun, Hans et al.

Part of Journal of Internal Medicine, p. 428-436, 2014

• DOI for Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study

Effects of Supplementation with Omega-3 Fatty Acids on Oxidative Stress and Inflammation in Patients with Alzheimer's Disease: The OmegAD Study

Freund-Levi, Yvonne; Vedin, Inger; Hjorth, Erik; Basun, Hans et al.

Part of Journal of Alzheimer's Disease, p. 823-831, 2014

• DOI for Effects of Supplementation with Omega-3 Fatty Acids on Oxidative Stress and Inflammation in Patients with Alzheimer's Disease: The OmegAD Study

High Tau Levels in Cerebrospinal Fluid Predict Rapid Decline and Increased Dementia Mortality in Alzheimer's Disease

Degerman Gunnarsson, Malin; Lannfelt, Lars; Ingelsson, Martin; Basun, Hans et al.

Part of Dementia and Geriatric Cognitive Disorders, p. 196-206, 2014

• DOI for High Tau Levels in Cerebrospinal Fluid Predict Rapid Decline and Increased Dementia Mortality in Alzheimer's Disease

Re-evaluation of clinical dementia diagnoses with pittsburgh compound B positron emission tomography

Degerman Gunnarsson, Malin; Lindau, M; Santillo, A F; Wall, Anders et al.

Part of Dementia and Geriatric Cognitive Disorders Extra, p. 472-481, 2013

• DOI for Re-evaluation of clinical dementia diagnoses with pittsburgh compound B positron emission tomography

The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ

Kalimo, Hannu; Lalowski, Maciej; Bogdanovic, Nenad; Philipson, Ola et al.

Part of Acta neuropathologica communications, p. 60, 2013

• DOI for The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ

Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia

Olsson, Bob; Hertze, Joakim; Lautner, Ronald; Zetterberg, Henrik et al.

Part of Journal of Alzheimer's Disease, p. 45-53, 2013

• DOI for Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia

Effects on Transthyretin in Plasma and Cerebrospinal Fluid by DHA-Rich n-3 Fatty Acid Supplementation in Patients with Alzheimer's Disease: The OmegAD Study

Faxen-Irving, Gerd; Freund-Levi, Yvonne; Eriksdotter-Jonhagen, Maria; Basun, Hans et al.

Part of Journal of Alzheimer's Disease, p. 1-6, 2013

• DOI for Effects on Transthyretin in Plasma and Cerebrospinal Fluid by DHA-Rich n-3 Fatty Acid Supplementation in Patients with Alzheimer's Disease: The OmegAD Study

Omega-3 Fatty Acids Enhance Phagocytosis of Alzheimer's Disease-Related Amyloid-beta(42) by Human Microglia and Decrease Inflammatory Markers

Hjorth, Erik; Zhu, Mingqin; Toro, Veronica Cortes; Vedin, Inger et al.

Part of Journal of Alzheimer's Disease, p. 697-713, 2013

• DOI for Omega-3 Fatty Acids Enhance Phagocytosis of Alzheimer's Disease-Related Amyloid-beta(42) by Human Microglia and Decrease Inflammatory Markers
• Download full text (pdf) of Omega-3 Fatty Acids Enhance Phagocytosis of Alzheimer's Disease-Related Amyloid-beta(42) by Human Microglia and Decrease Inflammatory Markers

Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia

Olsson, Bob; Hertze, Joakim; Ohlsson, Mattias; Nägga, Katarina et al.

Part of Journal of Alzheimer's Disease, p. 673-679, 2013

• DOI for Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia

Effects of DHA- Rich n-3 Fatty Acid Supplementation on Gene Expression in Blood Mononuclear Leukocytes: The OmegAD Study

Vedin, Inger; Cederholm, Tommy; Freund-Levi, Yvonne; Basun, Hans et al.

Part of PLOS ONE, 2012

• DOI for Effects of DHA- Rich n-3 Fatty Acid Supplementation on Gene Expression in Blood Mononuclear Leukocytes: The OmegAD Study
• Download full text (pdf) of Effects of DHA- Rich n-3 Fatty Acid Supplementation on Gene Expression in Blood Mononuclear Leukocytes: The OmegAD Study

Extreme Stability of Chitotriosidase in Cerebrospinal Fluid makes it a Suitable Marker for Microglial Activation in Clinical Trials

Olsson, Bob; Malmestrom, Clas; Basun, Hans; Annas, Peter et al.

Part of Journal of Alzheimer's Disease, p. 273-276, 2012

• DOI for Extreme Stability of Chitotriosidase in Cerebrospinal Fluid makes it a Suitable Marker for Microglial Activation in Clinical Trials

Longitudinal Stability Evaluation of Biomarkers and Their Correlation in Cerebrospinal Fluid and Plasma from Patients with Alzheimer's Disease

Höglund, Kina; Bogstedt, Anna; Fabre, Susanne; Aziz, Ali et al.

Part of Journal of Alzheimer's Disease, p. 939-947, 2012

• DOI for Longitudinal Stability Evaluation of Biomarkers and Their Correlation in Cerebrospinal Fluid and Plasma from Patients with Alzheimer's Disease

Influence of Lithium Treatment on GDNF Serum and CSF Concentrations in Patients with Early Alzheimer΄s Disease

Straten, Guido; Saur, Ralf; Laske, Christoph; Gasser, Thomas et al.

Part of Current Alzheimer research, p. 853-859, 2011

Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease

Wesnes, K; Edgar, C.; Andreasen, N.; Annas, P. et al.

Part of Acta Neurologica Scandinavica, p. 270-277, 2010

• DOI for Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease

Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls

Sundelöf, Johan; Sundström, Johan; Hansson, Oskar; Eriksdotter-Jönhagen, Maria et al.

Part of Journal of Alzheimer's Disease, p. 1223-1230, 2010

• DOI for Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls

Cystatin C Levels are Positively Correlated with both Aβ₄₂ and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls

Sundelöf, Johan; Sundstrom, Johan; Hansson, Oskar; Eriksdotter-Jönhagen, Maria et al.

Part of Journal of Alzheimer's Disease, p. 471-478, 2010

• DOI for Cystatin C Levels are Positively Correlated with both Aβ₄₂ and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls

Reduced prostaglandin F_2α release from blood mononuclear leukocytes after oral supplementation of ω3 fatty acids: the OmegAD study

Vedin, Inger; Cederholm, Tommy; Freund-Levi, Yvonne; Basun, Hans et al.

Part of Journal of Lipid Research, p. 1179-1185, 2010

• DOI for Reduced prostaglandin F_2α release from blood mononuclear leukocytes after oral supplementation of ω3 fatty acids: the OmegAD study

Systemic tocopherols and F2-isoprostanes and the risk of Alzheimer's disease and dementia: a prospective population-based study

Sundelöf, Johan; Kilander, Lena; Helmersson, Johanna; Larsson, Anders et al.

Part of Journal of Alzheimer's Disease, p. 71-78, 2009

• DOI for Systemic tocopherols and F2-isoprostanes and the risk of Alzheimer's disease and dementia: a prospective population-based study

Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study

Irving, Gerd Faxén; Freund-Levi, Yvonne; Eriksdotter-Jönhagen, Maria; Basun, Hans et al.

Part of Journal of The American Geriatrics Society, p. 11-17, 2009

• DOI for Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study

Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease

Leyhe, Thomas; Eschweiler, Gerhard W; Stransky, Elke; Gasser, Thomas et al.

Part of Journal of Alzheimer's Disease, p. 649-656, 2009

• DOI for Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease

Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study

Hampel, Harald; Ewers, Michael; Bürger, Katharina; Annas, Peter et al.

Part of Journal of Clinical Psychiatry, p. 922-931, 2009

Sällsynta mutationer leder till framtidens behandling

Ingelsson, Martin; Basun, Hans; Pettersson, Frida Ekholm; Kilander, Lena et al.

Part of Läkartidningen, p. 1396-1400, 2009

Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study

Freund-Levi, Yvonne; Hjorth, Erik; Lindberg, Catharina; Cederholm, Tommy et al.

Part of Dementia and Geriatric Cognitive Disorders, p. 481-490, 2009

• DOI for Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study

Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study

Sundelöf, Johan; Kilander, Lena; Helmersson, Johanna; Larsson, Anders et al.

Part of Journal of Alzheimer's Disease, p. 79-87, 2009

• DOI for Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study

Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation

Skoglund, Lena; Brundin, RoseMarie; Olofsson, Tommie; Kalimo, Hannu et al.

Part of Neurogenetics, p. 27-34, 2009

• DOI for Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation

Plasma β Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men: A Prospective, Population-Based Cohort Study

Sundelöf, Johan; Giedraitis, Vilmantas; Irizarry, Michael C; Sundström, Johan et al.

Part of Archives of Neurology, p. 256-63, 2008

• DOI for Plasma β Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men: A Prospective, Population-Based Cohort Study

Serum cystatin C and the risk of Alzheimer disease in elderly men

Sundelöf, Johan; Ärnlöv, J.; Ingelsson, E.; Sundström, J. et al.

Part of Neurology, p. 1072-1079, 2008

• DOI for Serum cystatin C and the risk of Alzheimer disease in elderly men

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms

Freund-Levi, Yvonne; Basun, Hans; Cederholm, Tommy; Faxén-Irving, Gerd et al.

Part of International Journal of Geriatric Psychiatry, p. 161-169, 2008

• DOI for Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms

Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study

Vedin, Inger; Cederholm, Tommy; Freund Levi, Yvonne; Basun, Hans et al.

Part of American Journal of Clinical Nutrition, p. 1616-1622, 2008

Clinical and Neuropathological Features of the Arctic APP Gene Mutation Causing Early-Onset Alzheimer Disease

Basun, Hans; Bogdanovic, Nenad; Ingelsson, Martin; Almkvist, Ove et al.

Part of Archives of Neurology, p. 499-505, 2008

• DOI for Clinical and Neuropathological Features of the Arctic APP Gene Mutation Causing Early-Onset Alzheimer Disease

Reduction of Phosphorylated Tau during Memantine Treatment of Alzheimer's Disease

Degerman Gunnarsson, Malin; Kilander, Lena; Basun, Hans; Lannfelt, Lars

Part of Dementia and Geriatric Cognitive Disorders, p. 247-252, 2007

• DOI for Reduction of Phosphorylated Tau during Memantine Treatment of Alzheimer's Disease

Underskatta inte värdet av transgena djurmodeller av Alzheimers sjukdom

Nilsson, Lars; Lannfelt, Lars; Basun, Hans; Nordberg, Agneta et al.

Part of Läkartidningen, p. 798-800, 2007

Longitudinal stability of CSF biomarkers in Alzheimer's disease

Blennow, Kaj; Zetterberg, Henrik; Minthon, Lennart; Lannfelt, Lars et al.

Part of Neuroscience Letters, p. 18-22, 2007

• DOI for Longitudinal stability of CSF biomarkers in Alzheimer's disease

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study - A randomized double-blind trial

Freund-Levi, Yvonne; Eriksdotter-Jonhagen, Maria; Cederholm, Tommy; Basun, Hans et al.

Part of Archives of Neurology, p. 1402-1408, 2006

• DOI for Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study - A randomized double-blind trial

Nutritional and cognitive relationships and long-term mortality in patients with various dementia disorders.

Faxén-Irving, Gerd; Basun, Hans; Cederholm, Tommy

Part of Age Ageing, p. 136-41, 2005

Nutrition education for care staff and possible effects on nutritional status in residents of sheltered accommodation.

Faxén-Irving, G; Andrén-Olsson, B; Geijerstam, A; Basun, H et al.

Part of Eur J Clin Nutr, p. 947-54, 2005

Konformationsförändrade proteiner orsakar neurodegenerativa sjukdomar

Ingelsson, Martin; Nilsson, Lars; Basun, Hans; Aquilonius, Sten-Magnus et al.

Part of Läkartidningen, p. 3542-3551, 2005

Clinical and molecular aspects of frontotemporal dementia.

Froelich-Fabre, Susanne; Skoglund, Lena; Ostojic, Jovanka; Kilander, Lena et al.

Part of Neurodegener Dis, p. 218-24, 2004

No evidence for tau duplications in frontal temporal dementia families showing genetic linkage to the tau locus in which tau mutations have not been found.

Johnson, J; Ostojic, J; Lannfelt, L; Glaser, A et al.

Part of Neurosci Lett, p. 99-101, 2004

The effect of nutritional intervention in elderly subjects residing in group-living for the demented.

Faxén-Irving, G; Andrén-Olsson, B; af Geijerstam, A; Basun, H et al.

Part of Eur J Clin Nutr, p. 221-7, 2002

Nya antikroppsbehandlingar mot alzheimers sjukdom: Behov av nationell förberedelse och samordning

Granberg, Tobias; Börjesson Hanson, Anne; Fällmar, David; Basun, Hans et al.

Part of Läkartidningen, 2024

Nya antikroppsbehandlingar mot Alzheimers sjukdom: [New Alzheimer’s treatments: a need for national preparations and coordination]

Granberg, Tobias; Börjesson Hanson, Anne; Fällmar, David; Basun, Hans et al.

Part of Läkartidningen, 2024

Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Matsunaga, Shinji; Kishi, Taro; Annas, Peter; Basun, Hans et al.

Part of Journal of Alzheimer's Disease, p. 403-410, 2015

• DOI for Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease

Lannfelt, Lars; Moller, Christer; Basun, Hans; Osswald, Gunilla et al.

Part of ALZHEIMERS RES THER, p. 16, 2014

• DOI for Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease
• Download full text (pdf) of Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease

Endpoints for trials in Alzheimer's disease: a European task force consensus.

Vellas, Bruno; Andrieu, Sandrine; Sampaio, Cristina; Coley, Nicola et al.

Part of Lancet Neurology, p. 436-450, 2008

• DOI for Endpoints for trials in Alzheimer's disease: a European task force consensus.

Disease-modifying trials in Alzheimer's disease: a European task force consensus.

Vellas, Bruno; Andrieu, Sandrine; Sampaio, Cristina; Basun, Hans et al.

Part of Lancet Neurology, p. 56-62, 2007

• DOI for Disease-modifying trials in Alzheimer's disease: a European task force consensus.

Kognitiva sjukdomar

Basun, Hans; Kilander, Lena

Part of Psykiatri, Studentlitteratur AB, 2024

Details of neuropathology in Arctic Alzheimer's disease

Kalimo, H.; Bogdanovic, N.; Callaghan, Paul O.; Bird, T. D. et al.

Part of Abstracts of the XVIIth International Congress of Neuropathology (ICN 2010), Salzburg, Austria, 11-15 September 2010, p. 22-23, 2010

• DOI for Details of neuropathology in Arctic Alzheimer's disease